Wikisage, the free encyclopedia of the second generation, is digital heritage
Levetiracetam: Difference between revisions
m (full paper) |
(→Links) |
||
| Line 24: | Line 24: | ||
Safraski J.-P.2015 | Safraski J.-P.2015 | ||
*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519029/pdf/i1535-7511-15-2-94.pdf Is There Equipoise Between Phenytoin and Levetiracetam for Seizure Prevention in Traumatic Brain Injury?] | *[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519029/pdf/i1535-7511-15-2-94.pdf Is There Equipoise Between Phenytoin and Levetiracetam for Seizure Prevention in Traumatic Brain Injury?] | ||
Vrielynck P. | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716601/pdf/ndt-9-963.pdf Current and emerging treatments for absence seizures in young patients] | |||
Jackson J.-L. et al.2015 | Jackson J.-L. et al.2015 | ||
Revision as of 00:53, 30 March 2016
(S)-2-(2-Oxopyrrolidin-1-yl)butanamide is an anticonvulsant medication used to treat epilepsy. It is the S-enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam.
Levetiracetam inhibits high-voltage-activated calcium channels and reduces calcium release from intraneural stores[1]
Extended release
Links
In myoclonic astatic epilepsy should be used with caution in children[2]
ATC
Trinka E., et al 2015 Pharmacotherapy for Status Epilepticus Drugs 75:1499
Safraski J.-P.2015
Vrielynck P. Current and emerging treatments for absence seizures in young patients
Jackson J.-L. et al.2015
Caviness J. N. Treatment of myoclonus
deWolfe & Szafarski Levetiracetam use in the critical care setting
- ↑ newer antiepileptic drugs
- ↑ Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy. BMC paediatrics 15 6
- ↑ http://www.whocc.no/atc_ddd_index/?code=N03AX14&showdescription=yes